{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:55:43Z","timestamp":1781661343796,"version":"3.54.5"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009160","name":"University of Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jtauto.2026.100379","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:49:28Z","timestamp":1780674568000},"page":"100379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A symposium update on the key perspectives in systemic sclerosis and systemic lupus erythematosus"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-5002","authenticated-orcid":false,"given":"Yves","family":"Renaudineau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Hedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Guery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Miyara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Delpuech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Belli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Puissant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtauto.2026.100379_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70003","article-title":"How (Ultra-)Rare gene variants improve our understanding of more common autoimmune and inflammatory diseases","volume":"7","author":"Belot","year":"2025","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.jtauto.2026.100379_bib2","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3389\/fimmu.2019.01525","article-title":"The role of epigenetics in Autoimmune\/inflammatory disease","volume":"10","author":"Surace","year":"2019","journal-title":"Front. Immunol."},{"issue":"423","key":"10.1016\/j.jtauto.2026.100379_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam8458","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","volume":"10","author":"Ah Kioon","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.jtauto.2026.100379_bib4","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/art.39781","article-title":"A novel mechanism for generating the interferon signature in lupus: opsonization of dead cells by complement and IgM","volume":"68","author":"Zhuang","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2026.100379_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type I interferons in autoimmune disease","volume":"14","author":"Crow","year":"2019","journal-title":"Annu. Rev. Pathol."},{"issue":"2","key":"10.1016\/j.jtauto.2026.100379_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4078\/jrd.2024.0129","article-title":"Pathogenesis of systemic sclerosis: an integrative review of recent advances","volume":"32","author":"Son","year":"2025","journal-title":"J Rheum Dis"},{"issue":"6","key":"10.1016\/j.jtauto.2026.100379_bib7","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1046\/j.1523-1755.2001.00045.x","article-title":"Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane","volume":"60","author":"Richards","year":"2001","journal-title":"Kidney Int."},{"issue":"7562","key":"10.1016\/j.jtauto.2026.100379_bib8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12016-025-09119-1","article-title":"Immunopathogenesis and therapeutics of systemic lupus erythematosus: an integrative review","volume":"68","author":"Lyu","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib10","article-title":"Pathophysiology of systemic sclerosis","volume":"50","author":"Thoreau","year":"2021","journal-title":"Presse Med."},{"key":"10.1016\/j.jtauto.2026.100379_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100199","article-title":"Immunological and translational key challenges in systemic lupus erythematosus: a symposium update","volume":"6","author":"Renaudineau","year":"2023","journal-title":"J Transl Autoimmun"},{"issue":"2","key":"10.1016\/j.jtauto.2026.100379_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/BOR.0000000000001072","article-title":"Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus - focus on juvenile-onset systemic lupus erythematosus","volume":"37","author":"Charras","year":"2025","journal-title":"Curr. Opin. Rheumatol."},{"issue":"2","key":"10.1016\/j.jtauto.2026.100379_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/BOR.0000000000000913","article-title":"Current views on lupus in children","volume":"35","author":"Smith","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"issue":"2\u20133","key":"10.1016\/j.jtauto.2026.100379_bib14","doi-asserted-by":"crossref","first-page":"J156","DOI":"10.1016\/j.jaut.2011.11.003","article-title":"Twin studies in autoimmune disease: genetics, gender and environment","volume":"38","author":"Bogdanos","year":"2012","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.jtauto.2026.100379_bib15","doi-asserted-by":"crossref","first-page":"J207","DOI":"10.1016\/j.jaut.2009.12.006","article-title":"Epigenetics and autoimmunity","volume":"34","author":"Brooks","year":"2010","journal-title":"J. Autoimmun."},{"issue":"SI2","key":"10.1016\/j.jtauto.2026.100379_bib16","doi-asserted-by":"crossref","first-page":"SI210","DOI":"10.1093\/rheumatology\/keac275","article-title":"Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE","volume":"62","author":"Charras","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.jtauto.2026.100379_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2024.100244","article-title":"Urinary soluble CD163 is useful as \"liquid biopsy\" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares","volume":"9","author":"Renaudineau","year":"2024","journal-title":"J Transl Autoimmun."},{"issue":"5","key":"10.1016\/j.jtauto.2026.100379_bib18","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201138","article-title":"Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus","volume":"218","author":"Hartl","year":"2021","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib19","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways","volume":"10","author":"Lopez-Isac","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jtauto.2026.100379_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100268","article-title":"Across ancestries, HLA-B *08:01 approximately DRB1 *03:01 (DR3) and HLA-DQA *01:02 (DR2) increase the risk to develop juvenile-onset systemic lupus erythematosus through low complement C4 levels","volume":"10","author":"Renaudineau","year":"2025","journal-title":"J Transl Autoimmun"},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/annrheumdis-2020-218558","article-title":"Genomic risk score impact on susceptibility to systemic sclerosis","volume":"80","author":"Bossini-Castillo","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2026.100379_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2025.110540","article-title":"Genetic variability associates with ancestry, age at disease onset, organ involvement and disease severity in juvenile-onset systemic lupus erythematosus","volume":"279","author":"Natoli","year":"2025","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib23","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1038\/s41467-020-19702-z","article-title":"Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jtauto.2026.100379_bib24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/art.42396","article-title":"Identification of mechanisms by which genetic susceptibility loci influence systemic sclerosis risk using functional genomics in primary T cells and monocytes","volume":"75","author":"Gonzalez-Serna","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.jtauto.2026.100379_bib25","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/art.41657","article-title":"Expression quantitative trait locus analysis in systemic sclerosis identifies new candidate genes associated with multiple aspects of disease pathology","volume":"73","author":"Kerick","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.jtauto.2026.100379_bib26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/art.41610","article-title":"Integrative analysis reveals a molecular stratification of systemic autoimmune diseases","volume":"73","author":"Barturen","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.jtauto.2026.100379_bib27","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.4049\/jimmunol.0802412","article-title":"IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation","volume":"182","author":"Garaud","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2026.100379_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.108937","article-title":"Long non-coding RNA xist contribution in systemic lupus erythematosus and rheumatoid arthritis","volume":"236","author":"Bost","year":"2022","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70074","article-title":"Escape from X chromosome inactivation as a driver of plasmacytoid DC heterogeneity in health and disease","volume":"336","author":"Barrat","year":"2025","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.jtauto.2026.100379_bib30","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231809","article-title":"Altered X-chromosome inactivation of the TLR7\/8 locus and heterogeneity of pDCs in systemic sclerosis","volume":"222","author":"Du","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2026.100379_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103451","article-title":"Common toll-like receptor 7 variants define disease risk and phenotypes in juvenile-onset systemic lupus erythematosus","volume":"155","author":"Renaudineau","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jtauto.2026.100379_bib32","article-title":"Type I interferon associated epistasis may contribute to early disease-onset and high disease activity in juvenile-onset","volume":"262","author":"Renaudineau","year":"2024","journal-title":"lupus. Clin Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/imr.13331","article-title":"Modulation of plasmacytoid dendritic cells response in inflammation and autoimmunity","volume":"323","author":"Ah Kioon","year":"2024","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1084\/jem.161.1.72","article-title":"Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease","volume":"161","author":"Sakaguchi","year":"1985","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jtauto.2026.100379_bib35","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/83784","article-title":"Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse","volume":"27","author":"Brunkow","year":"2001","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/83707","article-title":"X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy","volume":"27","author":"Wildin","year":"2001","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.jtauto.2026.100379_bib38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"issue":"62","key":"10.1016\/j.jtauto.2026.100379_bib39","doi-asserted-by":"crossref","first-page":"104733","DOI":"10.18632\/oncotarget.10914","article-title":"Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells","volume":"8","author":"Miyara","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.jtauto.2026.100379_bib40","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/annrheumdis-2011-200709","article-title":"Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions","volume":"71","author":"Mathian","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/eji.201948131","article-title":"Treg cell therapy: how cell heterogeneity can make the difference","volume":"51","author":"Giganti","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.jtauto.2026.100379_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jtauto.2026.100379_bib43","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American college of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2026.100379_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108774","article-title":"Combining multi-antigenic immunodot with indirect immunofluorescence on HEp-2 cells improves the diagnosis of systemic sclerosis","volume":"229","author":"Bost","year":"2021","journal-title":"Clin. Immunol."},{"issue":"9","key":"10.1016\/j.jtauto.2026.100379_bib45","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European league against Rheumatism\/American College of Rheumatology Classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2026.100379_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102524","article-title":"Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases","volume":"115","author":"Marziale","year":"2020","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.jtauto.2026.100379_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1055\/s-0037-1613055","article-title":"Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome","volume":"87","author":"Arvieux","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jtauto.2026.100379_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100274","article-title":"The added value of coupling anti-dsDNA and anti-chromatin antibodies in follow-up monitoring of systemic lupus erythematosus patients","volume":"10","author":"Carle","year":"2025","journal-title":"J Transl Autoimmun"},{"issue":"2","key":"10.1016\/j.jtauto.2026.100379_bib49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1101\/gr.100289.109","article-title":"Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus","volume":"20","author":"Javierre","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.jtauto.2026.100379_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109299","article-title":"Altered DNA methylation and gene expression predict disease severity in patients with Aicardi-Goutieres syndrome","volume":"249","author":"Garau","year":"2023","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77000-w","article-title":"Dephosphorylated uncarboxylated matrix-gla-protein as candidate biomarker for immune-mediated vascular remodeling and prognosis in pulmonary hypertension","volume":"14","author":"Tobal","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jtauto.2026.100379_bib52","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jnutbio.2012.02.012","article-title":"Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women","volume":"24","author":"Dalmeijer","year":"2013","journal-title":"J. Nutr. Biochem."},{"issue":"23","key":"10.1016\/j.jtauto.2026.100379_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13233526","article-title":"Plasma dephosphorylated-uncarboxylated matrix gla-protein in systemic sclerosis patients: biomarker potential for vascular calcification and inflammation","volume":"13","author":"Potjewijd","year":"2023","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/j.jtauto.2026.100379_bib54","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1093\/rheumatology\/keaf174","article-title":"Prostaglandin E1 restores endothelial progenitor cell function in systemic sclerosis","volume":"64","author":"Potjewijd","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"19","key":"10.1016\/j.jtauto.2026.100379_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914526","article-title":"Lupus nephritis risk factors and biomarkers: an update","volume":"24","author":"Renaudineau","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jtauto.2026.100379_bib56","doi-asserted-by":"crossref","first-page":"sfaf009","DOI":"10.1093\/ckj\/sfaf009","article-title":"CD163 detection in immune check-point inhibitors-related acute interstitial nephritis","volume":"18","author":"Perier","year":"2025","journal-title":"Clin. Kidney J."},{"issue":"5","key":"10.1016\/j.jtauto.2026.100379_bib57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MAJ.0000000000000569","article-title":"Significance of CD163-Positive macrophages in proliferative glomerulonephritis","volume":"350","author":"Li","year":"2015","journal-title":"Am. J. Med. Sci."},{"issue":"12","key":"10.1016\/j.jtauto.2026.100379_bib58","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1093\/rheumatology\/keaf446","article-title":"Urinary soluble CD163 is useful to predict lupus nephritis activity and to monitor standard-of-care therapy response","volume":"64","author":"Renaudineau","year":"2025","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.jtauto.2026.100379_bib59","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2015050511","article-title":"Urinary soluble CD163 in active renal vasculitis","volume":"27","author":"O'Reilly","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.jtauto.2026.100379_bib60","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2026.100379_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102869","article-title":"A cluster of type II interferon-regulated genes associates with disease activity in patients with systemic lupus erythematosus","volume":"132","author":"Siddiqi","year":"2022","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.jtauto.2026.100379_bib62","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2026.100379_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100090","article-title":"An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseases","volume":"4","author":"Bettacchioli","year":"2021","journal-title":"J Transl Autoimmun"},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","article-title":"High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.jtauto.2026.100379_bib65","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1093\/rheumatology\/keaf186","article-title":"Interferon-gamma release assay as an emergent powerful biomarker in systemic lupus erythematosus","volume":"64","author":"Renaudineau","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtauto.2026.100379_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2023.102416","article-title":"Low performance of interferon gamma release assay Quantiferon-TB gold coupled or not with Pst1\/3\/lipoglycan humoral detection to predict Mycobacterium tuberculosis complex disease in a low-burden area","volume":"143","author":"Martinez-Rivera","year":"2023","journal-title":"Tuberculosis (Edinb)."},{"key":"10.1016\/j.jtauto.2026.100379_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100200","article-title":"Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus","volume":"6","author":"Renaudineau","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jtauto.2026.100379_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102912","article-title":"Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases","volume":"133","author":"Renaudineau","year":"2022","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003503","article-title":"PD-1\/PD-L1 governed cross-talk of exhausted CD8(+) T and memory B cells in systemic lupus erythematosus","volume":"10","author":"Wang","year":"2024","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.jtauto.2026.100379_bib70","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","article-title":"Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2\/3 trials","volume":"81","author":"Bruce","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.jtauto.2026.100379_bib71","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of Anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jtauto.2026.100379_bib72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.jtauto.2026.100379_bib73","first-page":"1635","article-title":"A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to determine the effectiveness of the type I interferon receptor antibody, anifrolumab, in SYstemic sclerosis: DAISY study design and rationale","volume":"42","author":"Khanna","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib74","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.jtauto.2026.100379_bib75","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/jid.2015.188","article-title":"Suppression of T cell activation and collagen accumulation by an Anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis","volume":"135","author":"Guo","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100379_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"24","key":"10.1016\/j.jtauto.2026.100379_bib77","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jtauto.2026.100379_bib78","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00415-025-12958-9","article-title":"Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study","volume":"272","author":"Bril","year":"2025","journal-title":"J. Neurol."},{"issue":"23","key":"10.1016\/j.jtauto.2026.100379_bib79","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"10416","key":"10.1016\/j.jtauto.2026.100379_bib80","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"1S","key":"10.1016\/j.jtauto.2026.100379_bib81","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.bulcan.2024.06.008","article-title":"[prerequisite and organisation of health-care pathways for cell and gene therapies, using mesenchymal stromal cells (MSC) or chimeric antigen receptor (CAR) T cells, in patients with autoimmune systemic diseases]","volume":"112","author":"Castilla-Llorente","year":"2025","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.jtauto.2026.100379_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152786","article-title":"CAR T-cell therapy in SLE: a systematic review","volume":"74","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.jtauto.2026.100379_bib83","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jtauto.2026.100379_bib84","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"10.1016\/j.jtauto.2026.100379_bib85","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.jtauto.2026.100379_bib86","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.jtauto.2026.100379_bib87","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.jtauto.2026.100379_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur. J. Cancer"}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909026000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909026000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:24:55Z","timestamp":1781659495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909026000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":88,"alternative-id":["S2589909026000328"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2026.100379","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A symposium update on the key perspectives in systemic sclerosis and systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2026.100379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100379"}}